National Neuroscience Curriculum Initiative (NNCI)

National Neuroscience Curriculum Initiative (NNCI): Includes online modules for genetics education in specific areas (genetic testing in autism/developmental disabilities, evaluating pharmacogenomic tests, and the potential use of polygenic risk scores). These can be used in the classroom or for self-learning. These developments have been described (Nurnberger et al, Journal of Clinical Psychiatry, 2018 and Besterman et al, JAMA Psychiatry, 2019).  


Collaboration with the American Association of Directors of Psychiatic Residency Training to educate psychiatrists in training about neuroscience. Includes a variety of teaching resources including progressive case conferences with lesson plans, expert videos, and published commentaries. Several topics are relevant to genetic counselors/genetic counseling students in training such as modules on autism and psychopharmacogenomics. Must register to access some components but registration is free. 



Type Website
CME Available No
Topic
Cost Free
Note


Date of Resource 2019

Genomic Competencies

Experts from the disciplines listed below have tagged this resource as fulfulling genomic competencies.

Pharmacist

  • Basic Genetic Concepts
    • B1:   To demonstrate an understanding of the basic genetic/genomic concepts and nomenclature
    • B2:   To recognize and appreciate the role of behavioral, social, and environmental factors (lifestyle, socioeconomic factors, pollutants, etc.) to modify or influence genetics in the manifestation of disease
  • Ethical, Legal and Social Implications (ELSI)
    • E1:   To understand the potential physical and/or psychosocial benefits, limitations and risk of genomic/pharmacogenomic information for individuals, family members and communities, especially with genomic/pharmacogenomic tests that may relate to predisposition to disease
  • Genetics and Disease
    • G1:   To understand the role of genetic factors in maintaining health and preventing disease
    • G2:   To assess the difference between clinical diagnosis of disease and identification of genetic predisposition to disease (genetic variation is not strictly correlated with disease manifestation)
    • G3:   To appreciate that pharmacogenomic testing may also reveal certain genetic disease predispositions (e.g. the Apo E4 polymorphism)
  • Pharmacogenetics/Pharmacogenomics
    • P3:   Recognize the availability of evidence based guidelines that synthesize information relevant to genomic/pharmacogenomic tests and selection of drug therapy (e.g. Clinical Pharmacogenomics Implementation Consortium)

Genetic Counselor

  • Genetics Expertise and Analysis